Journal
CNS DRUGS
Volume 20, Issue 4, Pages 281-291Publisher
ADIS INT LTD
DOI: 10.2165/00023210-200620040-00002
Keywords
-
Categories
Funding
- NATIONAL CANCER INSTITUTE [R01CA071358, R01CA100341] Funding Source: NIH RePORTER
- NCI NIH HHS [R01 CA100341, 2 R01 CA71358] Funding Source: Medline
Ask authors/readers for more resources
Nicotine replacement therapy (NRT) is an effective treatment for smoking cessation, but as with all such pharmacotherapies, the majority of smokers who use NRT products do not stop smoking or remain abstinent long term. Treatment outcome is affected by a range of individual-specific factors, as well as the pharmacokinetic profile of each NRT formulation. This has led to speculation that abstinence rates could be improved if NRT treatments were individually tailored to best match each individual's needs and preferences. There are also populations for whom special product and dosage considerations are warranted to maximise treatment safety. This paper reviews the rationale for NRT treatment, standard dose recommendations and recommendations for how to best match NRT treatment to the specific needs of individual smokers. We also review emerging evidence that genetic profiling may one day be a useful consideration for tailoring NRT treatment.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available